http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022096993-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e94a8ff5bf244e45b630d5198e4334 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 |
| filingDate | 2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3838298205999d4d78bbe6663475cbf |
| publicationDate | 2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022096993-A |
| titleOfInvention | External pharmaceutical composition |
| abstract | PROBLEM TO BE SOLVED: To provide an external pharmaceutical composition containing felbinac, isopropyl myristate and water, which has improved dispersion stability and is excellent in skin compatibility. SOLUTION: In a pharmaceutical composition for external use, felbinac, isopropyl myristate (2% by weight or more) and N-methyl-2-pyrrolidone (2% by weight or more) are blended to improve dispersion stability and provide a uniform suspension. It can form a turbid state and become familiar with the skin. [Selection diagram] None |
| priorityDate | 2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.